Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Upgrades

  • For AnaptysBio Inc ANAB, Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The stock has a 52-week-high of $36.06 and a 52-week-low of $18.20. At the end of the last trading period, AnaptysBio closed at $28.85.
  • According to Barclays, the prior rating for First Solar Inc FSLR was changed from Underweight to Equal-Weight. In the third quarter, First Solar showed an EPS of $0.46, compared to $0.42 from the year-ago quarter. At the moment, the stock has a 52-week-high of $148.20 and a 52-week-low of $59.60. First Solar closed at $145.57 at the end of the last trading period.
  • According to Morgan Stanley, the prior rating for Gogo Inc GOGO was changed from Underweight to Equal-Weight. For the second quarter, Gogo had an EPS of $0.17, compared to year-ago quarter EPS of $0.12. The stock has a 52-week-high of $23.69 and a 52-week-low of $11.57. At the end of the last trading period, Gogo closed at $14.22.
  • RBC Capital upgraded the previous rating for Norfolk Southern Corp NSC from Underperform to Sector Perform. Norfolk Southern earned $3.80 in the third quarter, compared to $3.06 in the year-ago quarter. The stock has a 52-week-high of $298.99 and a 52-week-low of $203.65. At the end of the last trading period, Norfolk Southern closed at $228.07.
  • JP Morgan upgraded the previous rating for Lennox International Inc LII from Underweight to Neutral. Lennox International earned $4.10 in the third quarter, compared to $3.40 in the year-ago quarter. The stock has a 52-week-high of $324.04 and a 52-week-low of $182.85. At the end of the last trading period, Lennox International closed at $233.57.
  • JP Morgan upgraded the previous rating for Carvana Co CVNA from Underweight to Neutral. Carvana earned $2.35 in the second quarter, compared to $0.26 in the year-ago quarter. At the moment, the stock has a 52-week-high of $240.58 and a 52-week-low of $12.90. Carvana closed at $13.53 at the end of the last trading period.
  • According to JP Morgan, the prior rating for Monster Beverage Corp MNST was changed from Neutral to Overweight. For the second quarter, Monster Beverage had an EPS of $0.51, compared to year-ago quarter EPS of $0.75. The stock has a 52-week-high of $99.81 and a 52-week-low of $71.78. At the end of the last trading period, Monster Beverage closed at $93.72.

See all analyst ratings upgrades.

 

Downgrades

  • For Abiomed Inc ABMD, Piper Sandler downgraded the previous rating of Overweight to Neutral. For the second quarter, Abiomed had an EPS of $1.30, compared to year-ago quarter EPS of $1.03. The current stock performance of Abiomed shows a 52-week-high of $368.97 and a 52-week-low of $219.84. Moreover, at the end of the last trading period, the closing price was at $252.08.
  • For Varonis Systems Inc VRNS, Craig-Hallum downgraded the previous rating of Buy to Hold. Varonis Systems earned $0.05 in the third quarter, compared to $0.05 in the year-ago quarter. The stock has a 52-week-high of $51.60 and a 52-week-low of $22.92. At the end of the last trading period, Varonis Systems closed at $26.77.
  • B of A Securities downgraded the previous rating for Inovio Pharmaceuticals Inc INO from Neutral to Underperform. In the second quarter, Inovio Pharmaceuticals showed an EPS of $0.46, compared to $0.39 from the year-ago quarter. The current stock performance of Inovio Pharmaceuticals shows a 52-week-high of $5.27 and a 52-week-low of $1.38. Moreover, at the end of the last trading period, the closing price was at $2.16.
  • According to Argus Research, the prior rating for Skechers USA Inc SKX was changed from Buy to Hold. For the third quarter, Skechers USA had an EPS of $0.55, compared to year-ago quarter EPS of $0.66. At the moment, the stock has a 52-week-high of $49.89 and a 52-week-low of $31.28. Skechers USA closed at $34.43 at the end of the last trading period.
  • Oppenheimer downgraded the previous rating for TuSimple Holdings Inc TSP from Outperform to Perform. For the third quarter, TuSimple Hldgs had an EPS of $0.50, compared to year-ago quarter EPS of $0.54. The current stock performance of TuSimple Hldgs shows a 52-week-high of $37.24 and a 52-week-low of $3.21. Moreover, at the end of the last trading period, the closing price was at $3.43.
  • For Ventas Inc VTR, Raymond James downgraded the previous rating of Strong Buy to Outperform. In the second quarter, Ventas showed an EPS of $0.72, compared to $0.73 from the year-ago quarter. At the moment, the stock has a 52-week-high of $64.02 and a 52-week-low of $35.33. Ventas closed at $39.13 at the end of the last trading period.
  • For Steven Madden Ltd SHOO, Wedbush downgraded the previous rating of Outperform to Neutral. In the second quarter, Steven Madden showed an EPS of $0.63, compared to $0.48 from the year-ago quarter. The stock has a 52-week-high of $49.84 and a 52-week-low of $26.36. At the end of the last trading period, Steven Madden closed at $29.87.
  • According to Barclays, the prior rating for Principal Financial Group Inc PFG was changed from Overweight to Equal-Weight. Principal Finl Gr earned $1.69 in the third quarter, compared to $1.69 in the year-ago quarter. The stock has a 52-week-high of $88.52 and a 52-week-low of $61.05. At the end of the last trading period, Principal Finl Gr closed at $88.13.
  • Canaccord Genuity downgraded the previous rating for Argo Blockchain PLC ARBK from Buy to Hold. For the second quarter, Argo Blockchain had an EPS of $0.82, compared to year-ago quarter EPS of $0.03. At the moment, the stock has a 52-week-high of $13.14 and a 52-week-low of $0.88. Argo Blockchain closed at $1.11 at the end of the last trading period.
  • For Varonis Systems Inc VRNS, Wells Fargo downgraded the previous rating of Overweight to Underweight. For the third quarter, Varonis Systems had an EPS of $0.05, compared to year-ago quarter EPS of $0.05. At the moment, the stock has a 52-week-high of $51.60 and a 52-week-low of $22.92. Varonis Systems closed at $26.77 at the end of the last trading period.
  • According to Deutsche Bank, the prior rating for Emerson Electric Co EMR was changed from Buy to Hold. In the fourth quarter, Emerson Electric showed an EPS of $1.53, compared to $1.21 from the year-ago quarter. The stock has a 52-week-high of $100.00 and a 52-week-low of $72.41. At the end of the last trading period, Emerson Electric closed at $86.60.
  • For Charles Schwab Corp SCHW, Credit Suisse downgraded the previous rating of Outperform to Neutral. Charles Schwab earned $1.10 in the third quarter, compared to $0.84 in the year-ago quarter. At the moment, the stock has a 52-week-high of $96.24 and a 52-week-low of $59.35. Charles Schwab closed at $79.67 at the end of the last trading period.
  • According to Cowen & Co., the prior rating for Instil Bio Inc TIL was changed from Outperform to Market Perform. In the second quarter, Instil Bio showed an EPS of $0.46, compared to $0.27 from the year-ago quarter. At the moment, the stock has a 52-week-high of $18.97 and a 52-week-low of $3.11. Instil Bio closed at $3.30 at the end of the last trading period.
  • According to Canaccord Genuity, the prior rating for Stryker Corp SYK was changed from Buy to Hold. In the third quarter, Stryker showed an EPS of $2.12, compared to $2.20 from the year-ago quarter. At the moment, the stock has a 52-week-high of $280.43 and a 52-week-low of $188.84. Stryker closed at $229.24 at the end of the last trading period.
  • According to RBC Capital, the prior rating for Clearwater Paper Corp CLW was changed from Outperform to Sector Perform. Clearwater Paper earned $1.83 in the third quarter, compared to $0.55 in the year-ago quarter. The current stock performance of Clearwater Paper shows a 52-week-high of $46.48 and a 52-week-low of $25.07. Moreover, at the end of the last trading period, the closing price was at $44.48.
  • According to RBC Capital, the prior rating for Union Pacific Corp UNP was changed from Sector Perform to Underperform. In the third quarter, Union Pacific showed an EPS of $3.19, compared to $2.57 from the year-ago quarter. The stock has a 52-week-high of $278.94 and a 52-week-low of $183.70. At the end of the last trading period, Union Pacific closed at $197.14.

See all analyst ratings downgrades.

 

Initiations

  • Cowen & Co. initiated coverage on Legend Biotech Corp LEGN with an Outperform rating. Legend Biotech earned $0.24 in the first quarter, compared to $0.30 in the year-ago quarter. The stock has a 52-week-high of $57.67 and a 52-week-low of $30.75. At the end of the last trading period, Legend Biotech closed at $49.82.
  • With a Buy rating, BTIG initiated coverage on Rocket Pharmaceuticals Inc RCKT. The price target seems to have been set at $35.00 for Rocket Pharmaceuticals. For the second quarter, Rocket Pharmaceuticals had an EPS of $0.83, compared to year-ago quarter EPS of $0.55. The stock has a 52-week-high of $24.18 and a 52-week-low of $7.57. At the end of the last trading period, Rocket Pharmaceuticals closed at $18.66.
  • With a Hold rating, Loop Capital initiated coverage on ACADIA Pharmaceuticals Inc ACAD. The price target seems to have been set at $17.00 for ACADIA Pharmaceuticals. For the second quarter, ACADIA Pharmaceuticals had an EPS of $0.21, compared to year-ago quarter EPS of $0.27. The current stock performance of ACADIA Pharmaceuticals shows a 52-week-high of $28.05 and a 52-week-low of $12.24. Moreover, at the end of the last trading period, the closing price was at $16.03.
  • Loop Capital initiated coverage on Compass Pathways PLC CMPS with a Buy rating. The price target for Compass Pathways is set to $34.00. Compass Pathways earned $0.50 in the second quarter, compared to $0.44 in the year-ago quarter. The current stock performance of Compass Pathways shows a 52-week-high of $23.22 and a 52-week-low of $6.54. Moreover, at the end of the last trading period, the closing price was at $10.54.
  • With a Buy rating, Loop Capital initiated coverage on Axsome Therapeutics Inc AXSM. The price target seems to have been set at $95.00 for Axsome Therapeutics. Axsome Therapeutics earned $1.06 in the second quarter, compared to $0.86 in the year-ago quarter. At the moment, the stock has a 52-week-high of $71.98 and a 52-week-low of $20.63. Axsome Therapeutics closed at $45.15 at the end of the last trading period.
  • Truist Securities initiated coverage on Evolent Health Inc EVH with a Hold rating. The price target for Evolent Health is set to $33.00. In the second quarter, Evolent Health showed an EPS of $0.10, compared to $0.02 from the year-ago quarter. At the moment, the stock has a 52-week-high of $39.78 and a 52-week-low of $21.36. Evolent Health closed at $31.81 at the end of the last trading period.
  • Alliance Global Partners initiated coverage on Reviva Pharmaceuticals Holdings Inc RVPH with a Buy rating. The price target for Reviva Pharmaceuticals is set to $16.00. In the second quarter, Reviva Pharmaceuticals showed an EPS of $0.29, compared to $0.12 from the year-ago quarter. The current stock performance of Reviva Pharmaceuticals shows a 52-week-high of $4.50 and a 52-week-low of $0.53. Moreover, at the end of the last trading period, the closing price was at $3.92.
  • B. Riley Securities initiated coverage on PDS Biotechnology Corp PDSB with a Buy rating. The price target for PDS Biotechnology is set to $10.00. In the second quarter, PDS Biotechnology showed an EPS of $0.20, compared to $0.03 from the year-ago quarter. The current stock performance of PDS Biotechnology shows a 52-week-high of $8.47 and a 52-week-low of $2.89. Moreover, at the end of the last trading period, the closing price was at $5.24.
  • BMO Capital initiated coverage on AMC Entertainment Holdings Inc AMC with an Outperform rating. The price target for AMC Entertainment is set to $6.50. AMC Entertainment earned $0.20 in the second quarter, compared to $0.71 in the year-ago quarter. The current stock performance of AMC Entertainment shows a 52-week-high of $34.33 and a 52-week-low of $5.47. Moreover, at the end of the last trading period, the closing price was at $6.66.
  • Credit Suisse initiated coverage on Tronox Holdings PLC TROX with an Underperform rating. The price target for Tronox Holdings is set to $10.00. For the third quarter, Tronox Holdings had an EPS of $0.69, compared to year-ago quarter EPS of $0.72. The stock has a 52-week-high of $25.95 and a 52-week-low of $11.14. At the end of the last trading period, Tronox Holdings closed at $12.00.
  • With a Buy rating, Loop Capital initiated coverage on Karuna Therapeutics Inc KRTX. The price target seems to have been set at $288.00 for Karuna Therapeutics. In the second quarter, Karuna Therapeutics showed an EPS of $2.17, compared to $1.17 from the year-ago quarter. At the moment, the stock has a 52-week-high of $278.25 and a 52-week-low of $92.26. Karuna Therapeutics closed at $219.34 at the end of the last trading period.
  • Loop Capital initiated coverage on Sage Therapeutics Inc SAGE with a Hold rating. The price target for Sage Therapeutics is set to $41.00. For the second quarter, Sage Therapeutics had an EPS of $2.13, compared to year-ago quarter EPS of $1.83. The current stock performance of Sage Therapeutics shows a 52-week-high of $45.74 and a 52-week-low of $27.36. Moreover, at the end of the last trading period, the closing price was at $37.66.
  • Credit Suisse initiated coverage on The Chemours Co CC with an Underperform rating. The price target for Chemours is set to $24.00. Chemours earned $1.24 in the third quarter, compared to $1.27 in the year-ago quarter. At the moment, the stock has a 52-week-high of $44.95 and a 52-week-low of $22.56. Chemours closed at $28.63 at the end of the last trading period.
  • With a Neutral rating, HC Wainwright & Co. initiated coverage on Horizon Therapeutics PLC HZNP. The price target seems to have been set at $74.00 for Horizon Therapeutics. Horizon Therapeutics earned $1.07 in the second quarter, compared to $1.62 in the year-ago quarter. The stock has a 52-week-high of $117.49 and a 52-week-low of $57.84. At the end of the last trading period, Horizon Therapeutics closed at $62.32.
  • Jefferies initiated coverage on Edap TMS SA EDAP with a Buy rating. The price target for Edap TMS is set to $11.00. Edap TMS earned $0.06 in the second quarter, compared to $0.02 in the year-ago quarter. The stock has a 52-week-high of $9.52 and a 52-week-low of $5.54. At the end of the last trading period, Edap TMS closed at $9.48.
  • EF Hutton initiated coverage on Biomea Fusion Inc BMEA with a Buy rating. The price target for Biomea Fusion is set to $27.00. For the second quarter, Biomea Fusion had an EPS of $0.59, compared to year-ago quarter EPS of $0.33. The current stock performance of Biomea Fusion shows a 52-week-high of $14.20 and a 52-week-low of $2.84. Moreover, at the end of the last trading period, the closing price was at $11.00.
  • JP Morgan initiated coverage on NorthWestern Corp NWE with a Neutral rating. The price target for NorthWestern is set to $55.00. In the third quarter, NorthWestern showed an EPS of $0.42, compared to $0.65 from the year-ago quarter. At the moment, the stock has a 52-week-high of $63.06 and a 52-week-low of $48.68. NorthWestern closed at $52.83 at the end of the last trading period.
  • With a Buy rating, EF Hutton initiated coverage on Lantern Pharma Inc LTRN. The price target seems to have been set at $11.00 for Lantern Pharma. For the second quarter, Lantern Pharma had an EPS of $0.41, compared to year-ago quarter EPS of $0.21. At the moment, the stock has a 52-week-high of $8.30 and a 52-week-low of $4.19. Lantern Pharma closed at $4.19 at the end of the last trading period.
  • With a Buy rating, EF Hutton initiated coverage on Exelixis Inc EXEL. The price target seems to have been set at $28.00 for Exelixis. The stock has a 52-week-high of $23.40 and a 52-week-low of $14.87. At the end of the last trading period, Exelixis closed at $16.58.
  • EF Hutton initiated coverage on Regeneron Pharmaceuticals Inc REGN with a Buy rating. The price target for Regeneron Pharmaceuticals is set to $851.00. In the second quarter, Regeneron Pharmaceuticals showed an EPS of $9.77, compared to $25.80 from the year-ago quarter. The current stock performance of Regeneron Pharmaceuticals shows a 52-week-high of $761.04 and a 52-week-low of $538.01. Moreover, at the end of the last trading period, the closing price was at $748.75.
  • With a Buy rating, EF Hutton initiated coverage on Intellia Therapeutics Inc NTLA. The price target seems to have been set at $130.00 for Intellia Therapeutics. For the second quarter, Intellia Therapeutics had an EPS of $1.33, compared to year-ago quarter EPS of $1.01. The current stock performance of Intellia Therapeutics shows a 52-week-high of $119.65 and a 52-week-low of $37.08. Moreover, at the end of the last trading period, the closing price was at $52.78.
  • With a Buy rating, EF Hutton initiated coverage on Jasper Therapeutics Inc JSPR. The price target seems to have been set at $4.00 for Jasper Therapeutics. For the second quarter, Jasper Therapeutics had an EPS of $0.29, compared to year-ago quarter EPS of $4.00. At the moment, the stock has a 52-week-high of $8.12 and a 52-week-low of $0.71. Jasper Therapeutics closed at $0.73 at the end of the last trading period.
  • Stifel initiated coverage on OptimizeRx Corp OPRX with a Buy rating. The price target for OptimizeRx is set to $19.00. For the second quarter, OptimizeRx had an EPS of $0.04, compared to year-ago quarter EPS of $0.10. The stock has a 52-week-high of $64.22 and a 52-week-low of $13.33. At the end of the last trading period, OptimizeRx closed at $15.41.

See all analyst ratings initiations.

Posted In: BZI-RatingsUpgradesDowngradesInitiationIntraday UpdateAnalyst Ratings